A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DESTINY-Gastric03)
Inoguchi Akihiro
DAIICHI SANKYO Co.,Ltd.
1-2-58, Hiromachi, Shinagawa-ku, Tokyo
+81-3-6225-1111
dsclinicaltrial@daiichisankyo.co.jp
Contact for Clinical Trial Information
DAIICHI SANKYO Co.,Ltd.
1-2-58, Hiromachi, Shinagawa-ku, Tokyo
+81-3-6225-1111
dsclinicaltrial@daiichisankyo.co.jp
Recruiting
Nov. 18, 2020
May. 17, 2021
250
Interventional
randomized controlled trial
open(masking not used)
active control
parallel assignment
treatment purpose
1. Male and female participants must be at least 18 years of age (20 years of age in Japan)
2. Disease Characteristics:
Locally advanced, unresectable, or metastatic disease based on most recent imaging. For Part 1, 2, 3a pathologically documented adenocarcinoma of the stomach, GEJ, or esophagus, HER2-positive (IHC 3+ or IHC 2+/ISH-positive) based on existing local tissue testing results. For Part 3b, pathologically documented adenocarcinoma of the stomach, GEJ, or esophagus, HER2-low (IHC 2+/ISH-negative or IHC 1+) based on existing local tissue testing results.
3. For Part 1, progression on or after at least one prior trastuzumab-containing regimen. Previously untreated for unresectable or metastatic adenocarcinoma of the stomach, GEJ, or esophagus, with HER2-positive (Part 2 and Part 3, Arm 3A) or HER2-low (Part 3, Arm 3B) status
4. Has measurable target disease assessed by the Investigator based on RECIST version 1.1
5. Has protocol-defined adequate organ function including cardiac, renal and hepatic function
6. If of reproductive potential, agrees to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months (female) or 6 months (male) after last dose of study drug.
1. History of active primary immunodeficiency, known HIV, active HBV or HCV infection, or active tuberculosis.
2. Uncontrolled intercurrent illness
3. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening
4. Lung-specific intercurrent clinically significant severe illnesses
5. Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
6. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).
7. Has spinal cord compression or clinically active central nervous system metastases.
18age old over
130age old under
Both
adenocarcinoma of the stomach, GEJ, or esophagus
Experimental: Arm 1A: T-DXd and 5-fluorouracil (5-FU)
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 1B:T-DXd and capecitabine
Drug: Capecitabine/Capecitabine: administered orally
Drug: Trastuzumab deruxtecan/T-DXd: administered as an IV infusion
Other Name: DS-8201a
Experimental: Arm 1C:T-DXd and durvalumab
Biological: Durvalumab/ Durvalumab: administered as an IV infusion/ Other Name: MEDI4736
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 1Da:T-DXd, oxaliplatin and 5-FU
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Oxaliplatin/ Oxaliplatin: administered as an IV infusion
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 1Db:T-DXd, oxaliplatin and capecitabine
Drug: Capecitabine/ Capecitabine: administered orally
Drug: Oxaliplatin/ Oxaliplatin: administered as an IV infusion
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 1Ea:T-DXd, durvalumab and 5-FU
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Biological: Durvalumab/ Durvalumab: administered as an IV infusion/ Other Name: MEDI4736
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 1Eb:T-DXd, durvalumab and capecitabine
Drug: Capecitabine/ Capecitabine: administered orally
Biological: Durvalumab/ Durvalumab: administered as an IV infusion/ Other Name: MEDI4736
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Active Comparator: Arm 2A: Trastuzumab, 5-FU/capecitabine, and cisplatin/oxaliplatin
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Capecitabine / Capecitabine: administered orally
Drug: Oxaliplatin/ Oxaliplatin: administered as an IV infusion
Biological: Trastuzumab/ Trastuzumab: administered as an IV infusion
Drug: Cisplatin/ Cisplatin: administered as an IV infusion
Experimental: Arm 2B: T-DXd monotherapy/ Drug: Trastuzumab deruxtecan
T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 2C: T-DXd, 5-FU or capecitabine, and oxaliplatin
Drug: Fluorouracil (5-FU) / 5-FU: administered as an IV infusion
Drug: Capecitabine / Capecitabine: administered orally
Drug: Oxaliplatin / Oxaliplatin: administered as an IV infusion
Drug: Trastuzumab deruxtecan / T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 2D: T-DXd, 5-FU or capecitabine, and Pembrolizumab
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Capecitabine/ Capecitabine: administered orally
Biological: Pembrolizumab/ Pembrolizumab: administered as an IV infusion / Other Name: MK-3475
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 2E: T-DXd and Pembrolizumab
Biological: Pembrolizumab/ Pembrolizumab: administered as an IV infusion / Other Name: MK-3475
Drug: Trastuzumab deruxtecan /T-DXd: administered as an IV infusion / Other Name: DS-8201a
Experimental: Arm 2F: T-DXd, 5-FU or capecitabine, and Pembrolizumab
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Capecitabine/ Capecitabine: administered orally
Biological: Pembrolizumab/ Pembrolizumab: administered as an IV infusion / Other Name: MK-3475
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 3A: T-DXd, 5-FU or capecitabine, and MEDI5752
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Capecitabine/ Capecitabine: administered orally
Drug: Volrustoming/ MEDI5752: administered as an IV infusion
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Experimental: Arm 3B: T-DXd, 5-FU or capecitabine, and MEDI5752
Drug: Fluorouracil (5-FU)/ 5-FU: administered as an IV infusion
Drug: Capecitabine/ Capecitabine: administered orally
Drug: Volrustoming/ MEDI5752: administered as an IV infusion
Drug: Trastuzumab deruxtecan/ T-DXd: administered as an IV infusion/ Other Name: DS-8201a
Part 1: To assess safety and tolerability, and to determine the recommended Phase 2 dose (RP2D) or the highest protocol-defined dose of T-DXd combinations with capecitabine, 5-fluorouracil, oxaliplatin, or durvalumab
Occurrence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and changes from baseline in laboratory parameters, vital signs, and electrocardiogram (ECG) results
Part 2 and Part 3: To assess the antitumor activity of T-DXd combinations at the RP2D
Endpoint assessed by Investigator per RECIST v1.1:
- Confirmed Objective Response Rate (ORR)
Part 1: To assess the antitumor activity of T-DXd combinations
Endpoints assessed by Investigator per RECIST v1.1:
- Confirmed ORR
- Disease control rate (DCR)
- Duration of response (DoR)
- Progression-free survival (PFS)
- Overall survival (OS)
Part 2 and Part 3: To assess the antitumor activity of T-DXd combinations
Endpoints assessed by Investigator per RECIST v1.1:
- Disease control rate (DCR)
- Duration of response (DoR)
- Progression-free survival (PFS)
- Overall survival (OS)
Part 2 and Part 3: To assess the safety and tolerability of T-DXd monotherapy and T-DXd combination regimens
Occurrence of adverse events (AEs), serious adverse events (SAEs), and changes from baseline in laboratory parameters, vital signs, body weight, and electrocardiogram(ECG) results
To assess the pharmacokinetics of T-DXd, total anti-HER2 antibody, MAAA-1181, durvalumab, and MEDI5752 in all arms
- Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181 in all arms
- Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab
- Serum concentrations of MEDI5752 in study arms including T-DXd in combination with MEDI5752
To investigate the immunogenicity of T-DXd, durvalumab and MEDI5752
Presence of ADAs for T-DXd, durvalumab and MEDI5752 (in study arms including T-DXd and durvalumab, and T-DXd and MEDI5752, respectively)
To assess antitumor activity based on comparison of local HER2 results with central retrospective HER2 testing from baseline tumor samples
Comparison of ORR, DCR, DoR, PFS, OS between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
DAIICHI SANKYO Co.,Ltd.
AstraZeneca
Applicable
National Cancer Ctr IRB#2-j
5-1-1 Tsukiji, Chuo-ku, Tokyo
+81-3-3542-2511
Chiken_CT@ml.res.ncc.go.jp
Approval
Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting Materials: Informed Consent Form (ICF)
Time Frame: Study start to completion date
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home
